WASHINGTON, DC (August 10, 2020) — Today Lisa Steelman is joining the Association for Accessible Medicines (AAM). As Vice President, State Government Affairs, she serves as a senior strategist and lobbyist in partnership with the Senior Vice President, Government Affairs, Chris Bowlin, and other members of the State Government Affairs team to represent AAM and its member companies’ interests before state legislators, regulators and other state and local governmental entities. Lisa monitors legislation and regulation concerning the generic pharmaceutical industry in all 50 states, the District of Columbia and local jurisdictions. In addition, she identifies public policy priorities and devises and implements state-based strategies to advance AAM’s legislative, regulatory and political agenda.
Lisa joins AAM at a time of great challenge for the generics and biosimilars industry given the impact of COVID-19 on the health care system. Many states have truncated their legislative schedules, but misguided legislation remains a concern to our industry when the challenges to patient access in the states are growing greater, says Bowlin.
Lisa’s great skill set, excellent reputation and significant track record of success in previous positions will serve our industry well as we continue to advocate our industry’s priorities and educate lawmakers on the important role of generics and biosimilars in driving down the cost of pharmaceuticals.
Lisa came to AAM from the Association of Dental Support Organizations, where, as Senior Vice President for Alliance Development and Government Relations, she contributed to the five-year strategic plan and was responsible for realigning staff and consultants to execute plan deliverables. In this role she built a grassroots, advocacy and public relations strategy across multiple states and stewarded alliances to advance key issues. Previously, Lisa held the position of Regional Director, State Governmental Affairs, with Novartis Pharmaceuticals, where she led an industry-wide biosimilars legislative campaign.
Lisa attended Southern Illinois University and has an MBA in Healthcare Administration from Regis University.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.